Peptide Atlas · Peptide

Retatrutide

Retatrutide (LY3437943) is a single peptide that agonizes three receptors: glucagon, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

emerging

provisional
2 citations
0 discussions
0 followers
LY3437943

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Retatrutide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Discovery and phase 1 proof of concept of the triple agonist LY3437943	emerging	pmid 35985340
Phase 2 randomized trial in obesity	emerging	pmid 37366315

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.